Alfonso Jesús
Domínguez-Gil Hurlé
Profesor Emérito Honorífico
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (73)
2016
-
Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients
Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355
-
Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study
Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39
2015
-
CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman
Clinical drug investigation, Vol. 35, Núm. 1, pp. 61-66
2014
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study
Patient Preference and Adherence, Vol. 7, pp. 729-739
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2011
-
Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma
Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
2010
-
Biosimilars: Assessment of efficacy, safety and cost
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 25-28
-
Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment
Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50
2009
-
Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: An observational, open-label, multicentre study
Drugs and Aging, Vol. 26, Núm. 7, pp. 617-626
-
Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients
Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766
-
Hyperhidrosis in association with efavirenz
AIDS Patient Care and STDs, Vol. 23, Núm. 3, pp. 143-145
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis
Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280
2008
-
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Núm. 4, pp. 948-954
-
Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy
Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489
2007
-
Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain
Clinical Drug Investigation, Vol. 27, Núm. 3, pp. 197-205
-
El Instituto para el Uso Seguro de los Medicamentos (ISMP-España)
Farmaceutico Hospitales, pp. 18-25